The certificate, awarded by the competent health authority, validates the robustness of the laboratory's management and control model, and reaffirms its commitment to pharmaceutical safety, traceability, and quality, pillars that have guided its activity for over 75 years.
According to Francesc Balletbó, CEO of Acofarma, “this renewal comes at a key moment for the company. In Spain, the formulation market is undergoing a process of concentration in the hands of large multinationals, while we continue to defend the current community pharmacy model, because we are part of it. Being owned by cooperative pharmaceutical distribution allows us to make decisions always thinking about the real needs of pharmacists, not about business interests”.
A Growth Avenue for Pharmacies
Compounded medication, which allows for the customization of medicines to meet the individual needs of each person, is a differentiating element in patient care provided by the pharmacist, in addition to representing an opportunity for growth and profitability for the pharmacy. In the words of Montserrat Enrique, technical director of Acofarma, "our system, based on GMP standards, guarantees the adequate quality of our raw materials so that the pharmacist can prepare personalized medicines with complete safety."
International Presence and Commitment to Compounded Formulations
Based on this philosophy, the company maintains its commitment to **support pharmacy professionals** through various training activities, such as sponsoring the National Continuing Education Program in Magistral Formulation of the General Council of Pharmaceutical Colleges, or courses taught by local Pharmaceutical Colleges and formulation associations. In addition, it has its **own online training platform** (formacion.acofarma.com).
In addition, Acofarma continues to **expand its international presence**, with **Portugal** and **France** as some of its most relevant markets. The commitment of these countries to promoting this practice led Acofarma to organize a magistral formulation symposium in **Lisbon** last November. "The growth in Portugal is a testament to how other markets recognize the value of our business model, based on proximity to pharmacies and the advocacy for personalized medicine as an essential therapeutic tool," concludes Balletbó.